SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Ind-Ra assigns Shilpa Medicare’s long term rating at ‘A+’

16 Dec 2020 Evaluate

Credit rating agency-- India Ratings and Research (Ind-Ra) has assigned rating to Shilpa Medicare’s long term rating at ‘A+/Stable’ and short term rating at ‘A+/Stable/A1’ against the existing ratings of long term rating of ‘A (Stable)’ and short term rating of ‘A1’ assigned by ICRA.

Shilpa Medicare produces and exports consistently high-quality Active Pharmaceutical Ingredients Fine Chemicals, intermediates, herbal products and speciality chemical products using sophisticated technology, meticulously following international specifications.

Shilpa Medicare Share Price

594.50 23.65 (4.14%)
02-Jul-2026 13:53 View Price Chart
Peers
Company Name CMP
Sun Pharma. Inds. 1872.65
Dr. Reddys Labs. 1359.85
Cipla 1459.80
Zydus Lifesciences 1099.00
Lupin 2399.65
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through: